AtriCure
Trial Pipeline
BoxX-NoAF Clinical Trial
NCT06989775
Cryo NerVe Block Extremity AmputatioN RegIStry for Post Operative and pHantom Limb Pain
NCT06908538
Inappropriate Sinus Tachycardia Registry
NCT05107635
A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerves
NCT05110989
Tracking Results of Ablations to Combat AF Registry Generation 2
NCT05111015
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304
HEAL-IST IDE Trial
NCT05280093
CONVERGE Post-Approval Study (PAS)
NCT05393180
AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment
NCT03732794
FREEZE-AFIB Post-Market Study
NCT05089877
The cryoICE™ CryoAnalgesia Study For Pain Management in Post thoRacic Procedures Via intercOSTal Cryoanalgesia (FROST)
NCT02922153
AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)
NCT02701062
Stroke Feasibility Study
NCT01997905
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 4 | 1 |
What the Pipeline for AtriCure Shows
According to the ClinicalTrials.gov registry, AtriCure is linked to 13 US clinical trials across every stage of research activity. Of those, 5 studies are currently recruiting — about 38% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 31% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for AtriCure reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for AtriCure is Atrial Fibrillation with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.